An altered Lecam1/ICAM1 ratio on CD34+cells predicts leukemic progression in MDS patients.

被引：0
|
作者：
Buccisano, F [1 ]
Venditti, A [1 ]
Tamburini, A [1 ]
Del Poeta, G [1 ]
Maurillo, L [1 ]
Abruzzese, E [1 ]
Scornajenghi, KA [1 ]
Amadori, S [1 ]
机构：
[1] Univ Roma Tor Vergata, I-00173 Rome, Italy
来源：
BLOOD | 2001年 / 98卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2597
引用
收藏
页码：620A / 620A
页数：1
相关论文
共 50 条
  • [1] Lecam1/ICAM ratio identifies a distinct pattern on normal and myelodysplastic syndromes (MDS) bone marrow CD34+cells.
    Buccisano, F
    Venditti, A
    Del Poeta, G
    Maurillo, L
    Abruzzese, E
    Tamburini, A
    Del Principe, MI
    Amadori, S
    BLOOD, 2000, 96 (11) : 833A - 833A
  • [2] ALTERED EXPRESSION OF THE REPAIR GENES IN CD34+CELLS MAY BE RESPONSIBLE FOR FORMATION AND ACCUMULATION OF MUTATIONS IN MDS PATIENTS
    Valka, J.
    Belickova, M.
    Vesela, J.
    Stara, E.
    Planetova, B.
    Jonasova, A.
    Cermak, J.
    LEUKEMIA RESEARCH, 2015, 39 : S85 - S85
  • [3] Altered Expression of the Repair Genes in CD34+Cells May be Responsible for Formation and Accumulation of Mutations in MDS Patients
    Valka, Jan
    Belickova, Monika
    Vesela, Jitka
    Stara, Eliska
    Pejsova, Barbora
    Jonasova, Anna
    BLOOD, 2015, 126 (23)
  • [4] Efficient enrichment of CD34+cells NPM1 mutated AML patients
    Schneider, V
    Bullinger, L.
    Zhang, L.
    Rojewski, M.
    Hofmann, S.
    Goetz, M.
    Landshammer, A.
    Botzenhardt, U.
    Barth, T.
    Doehner, H.
    Greiner, J.
    ONKOLOGIE, 2012, 35 : 101 - 102
  • [5] Single Cell Transcriptome Analysis of CD34+Cells from Patients with RUNX1-Fpdmm at Different Stages of Disease Progression
    Bresciani, Erica
    Capaldo, Bian J.
    Kajdic, Amra
    Deuitch, Natalie T.
    Craft, Kathleen
    Chong, Shawn
    Elkahloun, Abdel G.
    Park, Morgan
    Young, Alice
    Young, David J.
    Meerzaman, Daoud
    Chen, Qingrong
    Liu, Paul P.
    BLOOD, 2024, 144 : 1325 - 1325
  • [6] Altered gene expression in CD34+cells from PBSC grafts from patients developing t-MDS following autologous transplantation for lymphoma.
    Li, Liang
    Wu, Xiwei
    Radich, Jerald P.
    Zhao, Lue Ping
    Francisco, Liton
    Komiya, Asako
    Damasco, Holly
    Forman, Stephen J.
    Bhatia, Smita
    Bhatia, Ravi
    BLOOD, 2006, 108 (11) : 659A - 659A
  • [7] Activated marrow CD8+T-lymphocytes influence marrow cellularity, fas antigen expression on CD34+cells and disease progression in patients with myelodysplastic syndromes (MDS).
    Symeonidis, A
    Karakantza, M
    Kouraklis, A
    Zoumbos, N
    BLOOD, 2001, 98 (11) : 276B - 276B
  • [8] Expression of TGF-b1, VEGF and bFGF in pheripheral blood CD34+cells, unpurified BMMNC and PBMNC of patients with myeloproliferative disease and MDS.
    Grossi, A
    Biscardi, M
    Gavazzi, S
    Balestri, F
    Fabbri, A
    Morfini, M
    BLOOD, 2001, 98 (11) : 279B - 279B
  • [9] No difference in WT1 mRNA expression in CD34+, rhodamine dull cells of normal individuals as compared to MDS and AML patients.
    van Dijk, JP
    van de Locht, LATF
    Raymakers, RAP
    de Witte, TM
    Mensink, EJBM
    BLOOD, 1998, 92 (10) : 255B - 255B
  • [10] Induced PD-1 Expression on Bone Marrow CD34+Cells from MDS Patients Treated with 5-Azacitadine in Combination with Nivolumab and/or Ipilimumab
    Yang, Hui
    Fang, Zhihong
    Clise-Dwyer, Karen
    Ruisaard, Kathryn
    Colla, Simona
    Ganan-Gomez, Irene
    Montalban-Bravo, Guillermo
    Soltysiak, Kelly
    Daver, Naval G.
    Jabbour, Elias J.
    Kantarjian, Hagop M.
    Garcia-Manero, Guillermo
    BLOOD, 2018, 132
12345